141 related articles for article (PubMed ID: 35129143)
1. Abatacept-based Graft-Versus-Host Disease Prophylaxis in Haplo-identical Hematopoietic Cell Transplant in a High-risk Cohort.
Raffa EH; Srinivasan A; Wall DA; Schechter T; Ali M; Krueger J; Chiang KY
J Pediatr Hematol Oncol; 2022 Oct; 44(7):383-387. PubMed ID: 35129143
[TBL] [Abstract][Full Text] [Related]
2. Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation.
Gaballa S; Ge I; El Fakih R; Brammer JE; Kongtim P; Tomuleasa C; Wang SA; Lee D; Petropoulos D; Cao K; Rondon G; Chen J; Hammerstrom A; Lombardi L; Alatrash G; Korbling M; Oran B; Kebriaei P; Ahmed S; Shah N; Rezvani K; Marin D; Bashir Q; Alousi A; Nieto Y; Qazilbash M; Hosing C; Popat U; Shpall EJ; Khouri I; Champlin RE; Ciurea SO
Cancer; 2016 Nov; 122(21):3316-3326. PubMed ID: 27404668
[TBL] [Abstract][Full Text] [Related]
3. Long-Term Follow-Up of Abatacept, Post-Transplantation Cyclophosphamide, and Sirolimus-Based Haploidentical Transplantation in Younger Patients with Nonmalignant Diseases.
Jaiswal SR; Agarwal M; Bhagawati G; Das BC; Baligar P; Garg M; Biswas S; Chakrabarti S
Transplant Cell Ther; 2024 Jun; 30(6):605.e1-605.e13. PubMed ID: 38490295
[TBL] [Abstract][Full Text] [Related]
4. Graft-versus-host Disease Prophylaxis With Abatacept Reduces Severe Acute Graft-versus-host Disease in Allogeneic Hematopoietic Stem Cell Transplant for Beta-thalassemia Major With Busulfan, Fludarabine, and Thiotepa.
Khandelwal P; Yeh RF; Yu L; Lane A; Dandoy CE; El-Bietar J; Davies SM; Grimley MS
Transplantation; 2021 Apr; 105(4):891-896. PubMed ID: 32467478
[TBL] [Abstract][Full Text] [Related]
5. Total Body Irradiation-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors.
Solomon SR; Sizemore CA; Sanacore M; Zhang X; Brown S; Holland HK; Morris LE; Bashey A
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1299-307. PubMed ID: 25797174
[TBL] [Abstract][Full Text] [Related]
6. Post-transplant cyclophosphamide versus anti-thymocyte globulin as graft- versus-host disease prophylaxis in haploidentical transplant.
Ruggeri A; Sun Y; Labopin M; Bacigalupo A; Lorentino F; Arcese W; Santarone S; Gülbas Z; Blaise D; Messina G; Ghavamzadeh A; Malard F; Bruno B; Diez-Martin JL; Koc Y; Ciceri F; Mohty M; Nagler A
Haematologica; 2017 Feb; 102(2):401-410. PubMed ID: 27758821
[TBL] [Abstract][Full Text] [Related]
7. Posttransplant Cyclophosphamide and Antithymocyte Globulin versus Posttransplant Cyclophosphamide as Graft-versus-Host Disease Prophylaxis for Peripheral Blood Stem Cell Haploidentical Transplants: Comparison of T Cell and NK Effector Reconstitution.
Makanga DR; Guillaume T; Willem C; Legrand N; Gagne K; Cesbron A; Gendzekhadze K; Peterlin P; Garnier A; Le Bourgeois A; Béné MC; Chevallier P; Retière C
J Immunol; 2020 Sep; 205(5):1441-1448. PubMed ID: 32747504
[TBL] [Abstract][Full Text] [Related]
8. Reduced-Intensity Conditioning and Dual T Lymphocyte Suppression with Antithymocyte Globulin and Post-Transplant Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Haploidentical Hematopoietic Stem Cell Transplants for Hematological Malignancies.
Law AD; Salas MQ; Lam W; Michelis FV; Thyagu S; Kim DDH; Lipton JH; Kumar R; Messner H; Viswabandya A
Biol Blood Marrow Transplant; 2018 Nov; 24(11):2259-2264. PubMed ID: 30009980
[TBL] [Abstract][Full Text] [Related]
9. Defibrotide combined with triple therapy including posttransplant cyclophosphamide, low dose rabbit anti-t-lymphocyte globulin and cyclosporine is effective in prevention of graft versus host disease after allogeneic peripheral blood stem cell transplantation for hematologic malignancies.
Akpinar S; Kayikci O; Tekgunduz E
Transfus Apher Sci; 2022 Feb; 61(1):103367. PubMed ID: 35120825
[TBL] [Abstract][Full Text] [Related]
10. Allogeneic cell therapy for patients who relapse after autologous stem cell transplantation.
Porter DL; Luger SM; Duffy KM; Stadtmauer EA; Laport G; Schuster SJ; Orloff G; Tsai D; McDaid K; Kathakali A; Leonard DG; Antin JH
Biol Blood Marrow Transplant; 2001; 7(4):230-8. PubMed ID: 11349810
[TBL] [Abstract][Full Text] [Related]
11. Post-transplant cyclophosphamide after matched sibling, unrelated and haploidentical donor transplants in patients with acute myeloid leukemia: a comparative study of the ALWP EBMT.
Sanz J; Galimard JE; Labopin M; Afanasyev B; Angelucci E; Ciceri F; Blaise D; Cornelissen JJ; Meijer E; Diez-Martin JL; Koc Y; Rovira M; Castagna L; Savani B; Ruggeri A; Nagler A; Mohty M;
J Hematol Oncol; 2020 May; 13(1):46. PubMed ID: 32375860
[TBL] [Abstract][Full Text] [Related]
12. In vivo T cell costimulation blockade with abatacept for acute graft-versus-host disease prevention: a first-in-disease trial.
Koura DT; Horan JT; Langston AA; Qayed M; Mehta A; Khoury HJ; Harvey RD; Suessmuth Y; Couture C; Carr J; Grizzle A; Johnson HR; Cheeseman JA; Conger JA; Robertson J; Stempora L; Johnson BE; Garrett A; Kirk AD; Larsen CP; Waller EK; Kean LS
Biol Blood Marrow Transplant; 2013 Nov; 19(11):1638-49. PubMed ID: 24047754
[TBL] [Abstract][Full Text] [Related]
13. Abatacept GVHD prophylaxis in unrelated hematopoietic cell transplantation for pediatric bone marrow failure.
Stenger EO; Watkins B; Rogowski K; Chiang KY; Haight A; Leung K; Qayed M; Raghunandan S; Suessmuth Y; Kean L; Horan J
Blood Adv; 2023 May; 7(10):2196-2205. PubMed ID: 36724508
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission.
Rashidi A; Hamadani M; Zhang MJ; Wang HL; Abdel-Azim H; Aljurf M; Assal A; Bajel A; Bashey A; Battiwalla M; Beitinjaneh AM; Bejanyan N; Bhatt VR; Bolaños-Meade J; Byrne M; Cahn JY; Cairo M; Ciurea S; Copelan E; Cutler C; Daly A; Diaz MA; Farhadfar N; Gale RP; Ganguly S; Grunwald MR; Hahn T; Hashmi S; Hildebrandt GC; Holland HK; Hossain N; Kanakry CG; Kharfan-Dabaja MA; Khera N; Koc Y; Lazarus HM; Lee JW; Maertens J; Martino R; McGuirk J; Munker R; Murthy HS; Nakamura R; Nathan S; Nishihori T; Palmisiano N; Patel S; Pidala J; Olin R; Olsson RF; Oran B; Ringden O; Rizzieri D; Rowe J; Savoie ML; Schultz KR; Seo S; Shaffer BC; Singh A; Solh M; Stockerl-Goldstein K; Verdonck LF; Wagner J; Waller EK; De Lima M; Sandmaier BM; Litzow M; Weisdorf D; Romee R; Saber W
Blood Adv; 2019 Jun; 3(12):1826-1836. PubMed ID: 31201170
[TBL] [Abstract][Full Text] [Related]
15. Phase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD.
Watkins B; Qayed M; McCracken C; Bratrude B; Betz K; Suessmuth Y; Yu A; Sinclair S; Furlan S; Bosinger S; Tkachev V; Rhodes J; Tumlin AG; Narayan A; Cribbin K; Gillespie S; Gooley TA; Pasquini MC; Hebert K; Kapoor U; Rogatko A; Tighiouart M; Kim S; Bresee C; Choi SW; Davis J; Duncan C; Giller R; Grimley M; Harris AC; Jacobsohn D; Lalefar N; Norkin M; Farhadfar N; Pulsipher MA; Shenoy S; Petrovic A; Schultz KR; Yanik GA; Waller EK; Levine JE; Ferrara JL; Blazar BR; Langston A; Horan JT; Kean LS
J Clin Oncol; 2021 Jun; 39(17):1865-1877. PubMed ID: 33449816
[TBL] [Abstract][Full Text] [Related]
16. A Prospective Pilot Study of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide and Ruxolitinib in Patients with Myelofibrosis.
Morozova EV; Barabanshikova MV; Moiseev IS; Shakirova AI; Barhatov IM; Ushal IE; Rodionov GG; Moiseev SI; Surkova EA; Lapin SV; Vlasova JJ; Rudakova TA; Darskaya EI; Baykov VV; Alyanski AL; Bondarenko SN; Afanasyev BV
Acta Haematol; 2021; 144(2):158-165. PubMed ID: 32325461
[TBL] [Abstract][Full Text] [Related]
17. Cotransplantation of bone marrow-derived mesenchymal stem cells in haploidentical hematopoietic stem cell transplantation in patients with severe aplastic anemia: an interim summary for a multicenter phase II trial results.
Liu Z; Zhang Y; Xiao H; Yao Z; Zhang H; Liu Q; Wu B; Nie D; Li Y; Pang Y; Fan Z; Li L; Jiang Z; Duan F; Li H; Zhang P; Gao Y; Ouyang L; Yue C; Xie M; Shi C; Xiao Y; Wang S
Bone Marrow Transplant; 2017 May; 52(5):704-710. PubMed ID: 28067873
[TBL] [Abstract][Full Text] [Related]
18. How I prevent GVHD in high-risk patients: posttransplant cyclophosphamide and beyond.
Rimando J; McCurdy SR; Luznik L
Blood; 2023 Jan; 141(1):49-59. PubMed ID: 35405017
[TBL] [Abstract][Full Text] [Related]
19. Calcineurin inhibitor--free graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide and brief-course sirolimus following reduced-intensity peripheral blood stem cell transplantation.
Solomon SR; Sanacore M; Zhang X; Brown S; Holland K; Morris LE; Bashey A
Biol Blood Marrow Transplant; 2014 Nov; 20(11):1828-34. PubMed ID: 25064745
[TBL] [Abstract][Full Text] [Related]
20. Impact of conditioning intensity in T-replete haplo-identical stem cell transplantation for acute leukemia: a report from the acute leukemia working party of the EBMT.
Rubio MT; Savani BN; Labopin M; Piemontese S; Polge E; Ciceri F; Bacigalupo A; Arcese W; Koc Y; Beelen D; Gülbas Z; Wu D; Santarone S; Tischer J; Afanasyev B; Schmid C; Giebel S; Mohty M; Nagler A
J Hematol Oncol; 2016 Mar; 9():25. PubMed ID: 26980295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
